| Original language | English (US) |
|---|---|
| Pages (from-to) | 413-415 |
| Number of pages | 3 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 144 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 2019 |
Keywords
- Genetic risk factors
- adult-onset asthma
- childhood-onset asthma
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology, Vol. 144, No. 2, 08.2019, p. 413-415.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Strength in numbers
T2 - The quest for asthma genes
AU - Vercelli, Donata
AU - Bleecker, Eugene R.
N1 - Funding Information: Disclosure of potential conflict of interest: D. Vercelli is currently supported by research grants from VIFOR/OM-Pharma, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute and previously received research support from Johnson & Johnson. E. R. Bleecker has undertaken clinical trials through his employers, Wake Forest School of Medicine and the University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Novartis, Regeneron, and Sanofi Genzyme and has served as a paid consultant for ALK-Abelló, AstraZeneca, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi Genzyme, and TEVA. Disclosure of potential conflict of interest: D. Vercelli is currently supported by research grants from VIFOR/ OM-Pharma, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute and previously received research support from Johnson & Johnson. E. R. Bleecker has undertaken clinical trials through his employers, Wake Forest School of Medicine and the University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Novartis, Regeneron, and Sanofi Genzyme and has served as a paid consultant for ALK-Abelló, AstraZeneca, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi Genzyme, and TEVA. Funding Information: Disclosure of potential conflict of interest: D. Vercelli is currently supported by research grants from VIFOR / OM-Pharma , the National Institute of Allergy and Infectious Diseases , and the National Heart, Lung, and Blood Institute and previously received research support from Johnson & Johnson . E. R. Bleecker has undertaken clinical trials through his employers, Wake Forest School of Medicine and the University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Novartis, Regeneron, and Sanofi Genzyme and has served as a paid consultant for ALK-Abelló, AstraZeneca, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi Genzyme, and TEVA.
PY - 2019/8
Y1 - 2019/8
KW - Genetic risk factors
KW - adult-onset asthma
KW - childhood-onset asthma
UR - http://www.scopus.com/inward/record.url?scp=85069853757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069853757&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2019.06.007
DO - 10.1016/j.jaci.2019.06.007
M3 - Editorial
C2 - 31229462
AN - SCOPUS:85069853757
SN - 0091-6749
VL - 144
SP - 413
EP - 415
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 2
ER -